Pulsenmore Debuts on Nasdaq, Expands FDA-Cleared Home Ultrasound in U.S.
Event summary
- Pulsenmore Ltd. (NASDAQ: PLSM) begins trading on Nasdaq on January 21, 2026, alongside its Tel Aviv Stock Exchange listing.
- Company offers the first and only FDA-authorized home-use prenatal ultrasound system.
- Platform combines proprietary ultrasound hardware, secure cloud-based image transmission, and clinical review workflows.
- Operates in select international markets with plans to expand across the U.S. healthcare system.
The big picture
Pulsenmore's Nasdaq debut marks a strategic pivot toward U.S. market expansion, leveraging its FDA-cleared home ultrasound technology. The move aligns with broader trends in telemedicine and digital health, where remote monitoring and patient-centric care are gaining traction. The company's ability to scale its platform across U.S. healthcare systems will be critical in determining its long-term success.
What we're watching
- Regulatory Headwinds
- Whether Pulsenmore can sustain FDA authorization while expanding into new U.S. markets.
- Market Penetration
- The pace at which Pulsenmore integrates with leading U.S. medical centers and hospitals.
- Investor Appeal
- How Nasdaq listing impacts Pulsenmore's ability to attract global investors aligned with its growth strategy.
Related topics